Relmada Therapeutics Company Profile (OTC:RLMDD)

About Relmada Therapeutics (OTC:RLMDD)

Relmada Therapeutics logo

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: N/A
  • Sub-Industry: N/A
  • Symbol: OTC:RLMDD
  • CUSIP: N/A
  • Web: www.relmada.com
Capitalization:
  • Market Cap: $9.03 million
  • Outstanding Shares: 11,999,000
Average Prices:
  • 50 Day Moving Avg: $3.11
  • 200 Day Moving Avg: $5.64
  • 52 Week Range: $11,999,000.00 - $2.00
P/E:
  • Trailing P/E Ratio: N/A
  • P/E Growth: 0.00
Profitability:
  • Return on Equity: -158.76%
  • Return on Assets: -111.66%
Debt:
  • Current Ratio: 2.66%
  • Quick Ratio: 2.66%
Misc:
  • Beta: 0.63
 

Frequently Asked Questions for Relmada Therapeutics (OTC:RLMDD)

What is Relmada Therapeutics' stock symbol?

Relmada Therapeutics trades on the OTC under the ticker symbol "RLMDD."

Who are some of Relmada Therapeutics' key competitors?

How do I buy Relmada Therapeutics stock?

Shares of Relmada Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Relmada Therapeutics' stock price today?

One share of Relmada Therapeutics stock can currently be purchased for approximately $4.72.


MarketBeat Community Rating for Relmada Therapeutics (OTC RLMDD)
Community Ranking:  1.4 out of 5 (star)
Outperform Votes:  23 (Vote Outperform)
Underperform Votes:  57 (Vote Underperform)
Total Votes:  80
MarketBeat's community ratings are surveys of what our community members think about Relmada Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Relmada Therapeutics (OTC:RLMDD) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Relmada Therapeutics (OTC:RLMDD)
Show:
No equities research coverage for this company has been tracked by MarketBeat.com

Earnings

Earnings History for Relmada Therapeutics (OTC:RLMDD)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for Relmada Therapeutics (OTC:RLMDD)
2017 EPS Consensus Estimate: ($0.70)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.16)($0.16)($0.16)
Q2 20171($0.18)($0.18)($0.18)
Q3 20171($0.18)($0.18)($0.18)
Q4 20171($0.18)($0.18)($0.18)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Relmada Therapeutics (OTC:RLMDD)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Relmada Therapeutics (OTC:RLMDD)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for Relmada Therapeutics (OTC:RLMDD)
Latest Headlines for Relmada Therapeutics (OTC:RLMDD)
Source:
No headlines for this company have been tracked by MarketBeat.com

Social

This page was last updated on 9/26/2017 by MarketBeat.com Staff